VPM
ANTX icon

Vanguard Portfolio Management’s AN2 Therapeutics ANTX Stock Holding History

Vanguard Portfolio Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$869K Buy
+179,594
New +$772K ﹤0.01% 2989

Other funds holding ANTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return

Vanguard Portfolio Management's ANTX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 179,594 shares worth $869K. The stake represents ﹤0.01% of the portfolio and ranks #2989 among its holdings.

40 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Vanguard Portfolio Management held 179,594 shares of AN2 Therapeutics worth $869K as of Q2 2026.
  • AN2 Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2989 holding.
  • 40 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.